Page 81 - Read Online

Cordero et al. Bioresorbable scaffolds in acute coronary syndrome

revascularisation rates are significantly lower in non- Patient consent
STEMI compared to STEMI patients, highlighting the All patients included in the registry provided the
unmet needs for validated and organised systems of informed consent.
care for non-STEMI patients. [43] Our results highlight
the role of revascularisation for ACS and the recurrence Ethics approval
of ischemic events. Stent type was not associated with
any of these events although our follow-up suggested The ethics committee of the hospital approved the
that revascularisation has higher impact than the other study protocol and informed consent.
techniques used.
REFERENCES
Our study has several limitations. The first is that a 1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman
very limited number of patients were treated with M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ,
BVS. Second, there may have been unmeasured Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman
confounders, details about the physician’s decision- JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler
making, or patient factors that are not captured ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW,
by the registry but account for the treatment Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ,
differences observed. Furthermore, our analysis Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS,
Woo D, Yeh RW, Turner MB; American Heart Association Statistics
uses observational, non-randomised data, and Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke
thus, associations between various treatments Statistics-2016 Update: a report from the American Heart Association.
and outcomes may be confounded by unmeasured Circulation 2016;133:e38-360.
variables. Finally, long-term outcomes could be 2. Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. J Am
modified by factors that were not captured by the Coll Cardiol 2013;61:1-11.
follow-up protocol that was employed at our outpatient 3. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F,
Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G,
centres. Nonetheless, since clinical features and Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D,
event rates are similar to previous reports, [4,36-38] we Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach
believe that our results should be representative of S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj
daily clinical practice and that our conclusions are S, Casselman F, Cuisset T, Erol C, Fitzsimons D, Halle M, Hamm C,
probably valid. Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip
GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints
In conclusion, our study supports the hypothesis that C, Luis Zamorano J; Management of Acute Coronary Syndromes
in Patients Presenting without Persistent ST-Segment Elevation of
coronary revascularisation using BVS is safe and the European Society of Cardiology. 2015 ESC Guidelines for the
effective in selected ACS patients. Percutaneous management of acute coronary syndromes in patients presenting
coronary revascularisation with stents is the without persistent ST-segment elevation: Task Force for the
cornerstone of ACS treatment but there are long-term Management of Acute Coronary Syndromes in Patients Presenting
complications of metallic devices that can be relevant. without Persistent ST-Segment Elevation of the European Society of
The use of BVS is a novel strategy with promising 4. Cardiology (ESC). Eur Heart J 2016;37:267-315.
Barrabes JA, Bardaji A, Jimenez-Candil J, del Nogal Saez F, Bodi V,
results, and there is an expectation that they will Basterra N, Marco E, Melgares R, Cunat de la Hoz J, Fernandez-Ortiz
prove useful in ACS selected patients. The long term A; investigators of DIOCLES study. Prognosis and management of
prognosis of BVS-treated patients remains unknown, acute coronary syndrome in Spain in 2012: the DIOCLES study. Rev
but given the growing number of patients being treated Esp Cardiol 2015;68:98-106.
with these devices, further evidence regarding their net 5. Cordero A, Lopez-Palop R, Carrillo P, Frutos A, Miralles S, Gunturiz
clinical benefit will likely emerge with additional time. C, Garcia-Carrilero M, Bertomeu-Martinez V. Changes in acute
coronary syndrome treatment and prognosis after implementation of
Authors’ contributions the infarction code in a hospital with a cardiac catheterization unit.
Rev Esp Cardiol (Engl Ed) 2016;69:754-9.
Manuscript’s conception and writting: A. Cordero, R. 6. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to
López-Palop and P. Carrillo transient bioresorbable scaffolds: change in paradigm of coronary
Data base fulfilment: A. Cordero, C. Gunturiz, M. revascularization in the upcoming decade? Eur Heart J 2012;33:16-
Garcia-Carrilero 7. 25b.
Ko DT, Tu JV, Samadashvili Z, Guo H, Alter DA, Cantor WJ, Hannan
Manuscript’s revision: A. Frutos, V. Bertomeu-Martinez EL. Temporal trends in the use of percutaneous coronary intervention
and coronary artery bypass surgery in New York State and Ontario.
Financial support and sponsorship Circulation 2010;121:2635-44.
None. 8. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di
Nisio M, Silletta MG, Maione A, Alfonso F, Clemmensen PM, Collet
JP, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Kappetein AP,
Conflicts of interest Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter
There are no conflicts of interest. D, Schauerte P, Sousa Uva M, Taggart DP, Torracca L, Valgimigli
74 Vessel Plus ¦ Volume 1 ¦ June 27, 2017